Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) EPS (Weighted Average and Diluted) (2016 - 2025)

Immucell (ICCC) has disclosed EPS (Weighted Average and Diluted) for 16 consecutive years, with -$0.02 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 75.0% year-over-year to -$0.02, compared with a TTM value of $0.28 through Sep 2025, up 157.14%, and an annual FY2024 reading of -$0.26, up 65.33% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.02 for Q3 2025 at Immucell, down from $0.06 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.16 in Q1 2025 and bottomed at -$0.3 in Q1 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.06, with a median of -$0.06 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 2300.0% in 2022, then surged 366.67% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.01 in 2021, then tumbled by 2300.0% to -$0.22 in 2022, then surged by 31.82% to -$0.15 in 2023, then skyrocketed by 153.33% to $0.08 in 2024, then plummeted by 125.0% to -$0.02 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ICCC at -$0.02 in Q3 2025, $0.06 in Q2 2025, and $0.16 in Q1 2025.